The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Immuno-oncology Clinical Trials Market Research Report 2025
Synopsis
The growth can be attributed to recent developments in immuno-oncology, changes in lifestyle brought on by urbanization predisposing populations to the rise of cancer, and the growing acceptability of targeted therapy.
The global Immuno-oncology Clinical Trials market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Immuno-oncology Clinical Trials is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Immuno-oncology Clinical Trials is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Immuno-oncology Clinical Trials in Solid Tumors is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Immuno-oncology Clinical Trials include Medpace, Novartis, Exscientia, Syneous Health, AstraZeneca, ICON plc, IQVIA Holdings, BioNtech and Covance, Inc., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Immuno-oncology Clinical Trials, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immuno-oncology Clinical Trials.
Report Scope
The Immuno-oncology Clinical Trials market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Immuno-oncology Clinical Trials market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Immuno-oncology Clinical Trials companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Medpace
Novartis
Exscientia
Syneous Health
AstraZeneca
ICON plc
IQVIA Holdings
BioNtech
Covance, Inc.
IO BIOTECH
Segment by Type
Phase I
Phase II
Phase III
Phase IV
Segment by Application
Solid Tumors
Hematological Cancer
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Immuno-oncology Clinical Trials companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
The growth can be attributed to recent developments in immuno-oncology, changes in lifestyle brought on by urbanization predisposing populations to the rise of cancer, and the growing acceptability of targeted therapy.
The global Immuno-oncology Clinical Trials market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Immuno-oncology Clinical Trials is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Immuno-oncology Clinical Trials is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Immuno-oncology Clinical Trials in Solid Tumors is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Immuno-oncology Clinical Trials include Medpace, Novartis, Exscientia, Syneous Health, AstraZeneca, ICON plc, IQVIA Holdings, BioNtech and Covance, Inc., etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Immuno-oncology Clinical Trials, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Immuno-oncology Clinical Trials.
Report Scope
The Immuno-oncology Clinical Trials market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Immuno-oncology Clinical Trials market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Immuno-oncology Clinical Trials companies, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Medpace
Novartis
Exscientia
Syneous Health
AstraZeneca
ICON plc
IQVIA Holdings
BioNtech
Covance, Inc.
IO BIOTECH
Segment by Type
Phase I
Phase II
Phase III
Phase IV
Segment by Application
Solid Tumors
Hematological Cancer
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Immuno-oncology Clinical Trials companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Immuno-oncology Clinical Trials Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 Phase I
1.2.3 Phase II
1.2.4 Phase III
1.2.5 Phase IV
1.3 Market by Application
1.3.1 Global Immuno-oncology Clinical Trials Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Solid Tumors
1.3.3 Hematological Cancer
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Immuno-oncology Clinical Trials Market Perspective (2019-2030)
2.2 Immuno-oncology Clinical Trials Growth Trends by Region
2.2.1 Global Immuno-oncology Clinical Trials Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Immuno-oncology Clinical Trials Historic Market Size by Region (2019-2024)
2.2.3 Immuno-oncology Clinical Trials Forecasted Market Size by Region (2025-2030)
2.3 Immuno-oncology Clinical Trials Market Dynamics
2.3.1 Immuno-oncology Clinical Trials Industry Trends
2.3.2 Immuno-oncology Clinical Trials Market Drivers
2.3.3 Immuno-oncology Clinical Trials Market Challenges
2.3.4 Immuno-oncology Clinical Trials Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Immuno-oncology Clinical Trials Players by Revenue
3.1.1 Global Top Immuno-oncology Clinical Trials Players by Revenue (2019-2024)
3.1.2 Global Immuno-oncology Clinical Trials Revenue Market Share by Players (2019-2024)
3.2 Global Immuno-oncology Clinical Trials Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Immuno-oncology Clinical Trials Revenue
3.4 Global Immuno-oncology Clinical Trials Market Concentration Ratio
3.4.1 Global Immuno-oncology Clinical Trials Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Immuno-oncology Clinical Trials Revenue in 2023
3.5 Immuno-oncology Clinical Trials Key Players Head office and Area Served
3.6 Key Players Immuno-oncology Clinical Trials Product Solution and Service
3.7 Date of Enter into Immuno-oncology Clinical Trials Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Immuno-oncology Clinical Trials Breakdown Data by Type
4.1 Global Immuno-oncology Clinical Trials Historic Market Size by Type (2019-2024)
4.2 Global Immuno-oncology Clinical Trials Forecasted Market Size by Type (2025-2030)
5 Immuno-oncology Clinical Trials Breakdown Data by Application
5.1 Global Immuno-oncology Clinical Trials Historic Market Size by Application (2019-2024)
5.2 Global Immuno-oncology Clinical Trials Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Immuno-oncology Clinical Trials Market Size (2019-2030)
6.2 North America Immuno-oncology Clinical Trials Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Immuno-oncology Clinical Trials Market Size by Country (2019-2024)
6.4 North America Immuno-oncology Clinical Trials Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Immuno-oncology Clinical Trials Market Size (2019-2030)
7.2 Europe Immuno-oncology Clinical Trials Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Immuno-oncology Clinical Trials Market Size by Country (2019-2024)
7.4 Europe Immuno-oncology Clinical Trials Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Immuno-oncology Clinical Trials Market Size (2019-2030)
8.2 Asia-Pacific Immuno-oncology Clinical Trials Market Growth Rate by Region: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Immuno-oncology Clinical Trials Market Size by Region (2019-2024)
8.4 Asia-Pacific Immuno-oncology Clinical Trials Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Immuno-oncology Clinical Trials Market Size (2019-2030)
9.2 Latin America Immuno-oncology Clinical Trials Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Immuno-oncology Clinical Trials Market Size by Country (2019-2024)
9.4 Latin America Immuno-oncology Clinical Trials Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Immuno-oncology Clinical Trials Market Size (2019-2030)
10.2 Middle East & Africa Immuno-oncology Clinical Trials Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Immuno-oncology Clinical Trials Market Size by Country (2019-2024)
10.4 Middle East & Africa Immuno-oncology Clinical Trials Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Medpace
11.1.1 Medpace Company Detail
11.1.2 Medpace Business Overview
11.1.3 Medpace Immuno-oncology Clinical Trials Introduction
11.1.4 Medpace Revenue in Immuno-oncology Clinical Trials Business (2019-2024)
11.1.5 Medpace Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Immuno-oncology Clinical Trials Introduction
11.2.4 Novartis Revenue in Immuno-oncology Clinical Trials Business (2019-2024)
11.2.5 Novartis Recent Development
11.3 Exscientia
11.3.1 Exscientia Company Detail
11.3.2 Exscientia Business Overview
11.3.3 Exscientia Immuno-oncology Clinical Trials Introduction
11.3.4 Exscientia Revenue in Immuno-oncology Clinical Trials Business (2019-2024)
11.3.5 Exscientia Recent Development
11.4 Syneous Health
11.4.1 Syneous Health Company Detail
11.4.2 Syneous Health Business Overview
11.4.3 Syneous Health Immuno-oncology Clinical Trials Introduction
11.4.4 Syneous Health Revenue in Immuno-oncology Clinical Trials Business (2019-2024)
11.4.5 Syneous Health Recent Development
11.5 AstraZeneca
11.5.1 AstraZeneca Company Detail
11.5.2 AstraZeneca Business Overview
11.5.3 AstraZeneca Immuno-oncology Clinical Trials Introduction
11.5.4 AstraZeneca Revenue in Immuno-oncology Clinical Trials Business (2019-2024)
11.5.5 AstraZeneca Recent Development
11.6 ICON plc
11.6.1 ICON plc Company Detail
11.6.2 ICON plc Business Overview
11.6.3 ICON plc Immuno-oncology Clinical Trials Introduction
11.6.4 ICON plc Revenue in Immuno-oncology Clinical Trials Business (2019-2024)
11.6.5 ICON plc Recent Development
11.7 IQVIA Holdings
11.7.1 IQVIA Holdings Company Detail
11.7.2 IQVIA Holdings Business Overview
11.7.3 IQVIA Holdings Immuno-oncology Clinical Trials Introduction
11.7.4 IQVIA Holdings Revenue in Immuno-oncology Clinical Trials Business (2019-2024)
11.7.5 IQVIA Holdings Recent Development
11.8 BioNtech
11.8.1 BioNtech Company Detail
11.8.2 BioNtech Business Overview
11.8.3 BioNtech Immuno-oncology Clinical Trials Introduction
11.8.4 BioNtech Revenue in Immuno-oncology Clinical Trials Business (2019-2024)
11.8.5 BioNtech Recent Development
11.9 Covance, Inc.
11.9.1 Covance, Inc. Company Detail
11.9.2 Covance, Inc. Business Overview
11.9.3 Covance, Inc. Immuno-oncology Clinical Trials Introduction
11.9.4 Covance, Inc. Revenue in Immuno-oncology Clinical Trials Business (2019-2024)
11.9.5 Covance, Inc. Recent Development
11.10 IO BIOTECH
11.10.1 IO BIOTECH Company Detail
11.10.2 IO BIOTECH Business Overview
11.10.3 IO BIOTECH Immuno-oncology Clinical Trials Introduction
11.10.4 IO BIOTECH Revenue in Immuno-oncology Clinical Trials Business (2019-2024)
11.10.5 IO BIOTECH Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
List of TablesList of Tables
Table 1. Global Immuno-oncology Clinical Trials Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of Phase I
Table 3. Key Players of Phase II
Table 4. Key Players of Phase III
Table 5. Key Players of Phase IV
Table 6. Global Immuno-oncology Clinical Trials Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 7. Global Immuno-oncology Clinical Trials Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 8. Global Immuno-oncology Clinical Trials Market Size by Region (2019-2024) & (US$ Million)
Table 9. Global Immuno-oncology Clinical Trials Market Share by Region (2019-2024)
Table 10. Global Immuno-oncology Clinical Trials Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 11. Global Immuno-oncology Clinical Trials Market Share by Region (2025-2030)
Table 12. Immuno-oncology Clinical Trials Market Trends
Table 13. Immuno-oncology Clinical Trials Market Drivers
Table 14. Immuno-oncology Clinical Trials Market Challenges
Table 15. Immuno-oncology Clinical Trials Market Restraints
Table 16. Global Immuno-oncology Clinical Trials Revenue by Players (2019-2024) & (US$ Million)
Table 17. Global Immuno-oncology Clinical Trials Market Share by Players (2019-2024)
Table 18. Global Top Immuno-oncology Clinical Trials Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-oncology Clinical Trials as of 2023)
Table 19. Ranking of Global Top Immuno-oncology Clinical Trials Companies by Revenue (US$ Million) in 2023
Table 20. Global 5 Largest Players Market Share by Immuno-oncology Clinical Trials Revenue (CR5 and HHI) & (2019-2024)
Table 21. Key Players Headquarters and Area Served
Table 22. Key Players Immuno-oncology Clinical Trials Product Solution and Service
Table 23. Date of Enter into Immuno-oncology Clinical Trials Market
Table 24. Mergers & Acquisitions, Expansion Plans
Table 25. Global Immuno-oncology Clinical Trials Market Size by Type (2019-2024) & (US$ Million)
Table 26. Global Immuno-oncology Clinical Trials Revenue Market Share by Type (2019-2024)
Table 27. Global Immuno-oncology Clinical Trials Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 28. Global Immuno-oncology Clinical Trials Revenue Market Share by Type (2025-2030)
Table 29. Global Immuno-oncology Clinical Trials Market Size by Application (2019-2024) & (US$ Million)
Table 30. Global Immuno-oncology Clinical Trials Revenue Market Share by Application (2019-2024)
Table 31. Global Immuno-oncology Clinical Trials Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 32. Global Immuno-oncology Clinical Trials Revenue Market Share by Application (2025-2030)
Table 33. North America Immuno-oncology Clinical Trials Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 34. North America Immuno-oncology Clinical Trials Market Size by Country (2019-2024) & (US$ Million)
Table 35. North America Immuno-oncology Clinical Trials Market Size by Country (2025-2030) & (US$ Million)
Table 36. Europe Immuno-oncology Clinical Trials Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 37. Europe Immuno-oncology Clinical Trials Market Size by Country (2019-2024) & (US$ Million)
Table 38. Europe Immuno-oncology Clinical Trials Market Size by Country (2025-2030) & (US$ Million)
Table 39. Asia-Pacific Immuno-oncology Clinical Trials Market Size Growth Rate by Region (US$ Million): 2019 VS 2023 VS 2030
Table 40. Asia-Pacific Immuno-oncology Clinical Trials Market Size by Region (2019-2024) & (US$ Million)
Table 41. Asia-Pacific Immuno-oncology Clinical Trials Market Size by Region (2025-2030) & (US$ Million)
Table 42. Latin America Immuno-oncology Clinical Trials Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 43. Latin America Immuno-oncology Clinical Trials Market Size by Country (2019-2024) & (US$ Million)
Table 44. Latin America Immuno-oncology Clinical Trials Market Size by Country (2025-2030) & (US$ Million)
Table 45. Middle East & Africa Immuno-oncology Clinical Trials Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 46. Middle East & Africa Immuno-oncology Clinical Trials Market Size by Country (2019-2024) & (US$ Million)
Table 47. Middle East & Africa Immuno-oncology Clinical Trials Market Size by Country (2025-2030) & (US$ Million)
Table 48. Medpace Company Detail
Table 49. Medpace Business Overview
Table 50. Medpace Immuno-oncology Clinical Trials Product
Table 51. Medpace Revenue in Immuno-oncology Clinical Trials Business (2019-2024) & (US$ Million)
Table 52. Medpace Recent Development
Table 53. Novartis Company Detail
Table 54. Novartis Business Overview
Table 55. Novartis Immuno-oncology Clinical Trials Product
Table 56. Novartis Revenue in Immuno-oncology Clinical Trials Business (2019-2024) & (US$ Million)
Table 57. Novartis Recent Development
Table 58. Exscientia Company Detail
Table 59. Exscientia Business Overview
Table 60. Exscientia Immuno-oncology Clinical Trials Product
Table 61. Exscientia Revenue in Immuno-oncology Clinical Trials Business (2019-2024) & (US$ Million)
Table 62. Exscientia Recent Development
Table 63. Syneous Health Company Detail
Table 64. Syneous Health Business Overview
Table 65. Syneous Health Immuno-oncology Clinical Trials Product
Table 66. Syneous Health Revenue in Immuno-oncology Clinical Trials Business (2019-2024) & (US$ Million)
Table 67. Syneous Health Recent Development
Table 68. AstraZeneca Company Detail
Table 69. AstraZeneca Business Overview
Table 70. AstraZeneca Immuno-oncology Clinical Trials Product
Table 71. AstraZeneca Revenue in Immuno-oncology Clinical Trials Business (2019-2024) & (US$ Million)
Table 72. AstraZeneca Recent Development
Table 73. ICON plc Company Detail
Table 74. ICON plc Business Overview
Table 75. ICON plc Immuno-oncology Clinical Trials Product
Table 76. ICON plc Revenue in Immuno-oncology Clinical Trials Business (2019-2024) & (US$ Million)
Table 77. ICON plc Recent Development
Table 78. IQVIA Holdings Company Detail
Table 79. IQVIA Holdings Business Overview
Table 80. IQVIA Holdings Immuno-oncology Clinical Trials Product
Table 81. IQVIA Holdings Revenue in Immuno-oncology Clinical Trials Business (2019-2024) & (US$ Million)
Table 82. IQVIA Holdings Recent Development
Table 83. BioNtech Company Detail
Table 84. BioNtech Business Overview
Table 85. BioNtech Immuno-oncology Clinical Trials Product
Table 86. BioNtech Revenue in Immuno-oncology Clinical Trials Business (2019-2024) & (US$ Million)
Table 87. BioNtech Recent Development
Table 88. Covance, Inc. Company Detail
Table 89. Covance, Inc. Business Overview
Table 90. Covance, Inc. Immuno-oncology Clinical Trials Product
Table 91. Covance, Inc. Revenue in Immuno-oncology Clinical Trials Business (2019-2024) & (US$ Million)
Table 92. Covance, Inc. Recent Development
Table 93. IO BIOTECH Company Detail
Table 94. IO BIOTECH Business Overview
Table 95. IO BIOTECH Immuno-oncology Clinical Trials Product
Table 96. IO BIOTECH Revenue in Immuno-oncology Clinical Trials Business (2019-2024) & (US$ Million)
Table 97. IO BIOTECH Recent Development
Table 98. Research Programs/Design for This Report
Table 99. Key Data Information from Secondary Sources
Table 100. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Immuno-oncology Clinical Trials Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 2. Global Immuno-oncology Clinical Trials Market Share by Type: 2023 VS 2030
Figure 3. Phase I Features
Figure 4. Phase II Features
Figure 5. Phase III Features
Figure 6. Phase IV Features
Figure 7. Global Immuno-oncology Clinical Trials Market Size Comparison by Application (2024-2030) & (US$ Million)
Figure 8. Global Immuno-oncology Clinical Trials Market Share by Application: 2023 VS 2030
Figure 9. Solid Tumors Case Studies
Figure 10. Hematological Cancer Case Studies
Figure 11. Immuno-oncology Clinical Trials Report Years Considered
Figure 12. Global Immuno-oncology Clinical Trials Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 13. Global Immuno-oncology Clinical Trials Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 14. Global Immuno-oncology Clinical Trials Market Share by Region: 2023 VS 2030
Figure 15. Global Immuno-oncology Clinical Trials Market Share by Players in 2023
Figure 16. Global Top Immuno-oncology Clinical Trials Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Immuno-oncology Clinical Trials as of 2023)
Figure 17. The Top 10 and 5 Players Market Share by Immuno-oncology Clinical Trials Revenue in 2023
Figure 18. North America Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 19. North America Immuno-oncology Clinical Trials Market Share by Country (2019-2030)
Figure 20. United States Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Canada Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 23. Europe Immuno-oncology Clinical Trials Market Share by Country (2019-2030)
Figure 24. Germany Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. France Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. U.K. Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Italy Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Russia Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Nordic Countries Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 31. Asia-Pacific Immuno-oncology Clinical Trials Market Share by Region (2019-2030)
Figure 32. China Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. Japan Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. South Korea Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. Southeast Asia Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. India Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Australia Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 39. Latin America Immuno-oncology Clinical Trials Market Share by Country (2019-2030)
Figure 40. Mexico Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Brazil Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 43. Middle East & Africa Immuno-oncology Clinical Trials Market Share by Country (2019-2030)
Figure 44. Turkey Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. Saudi Arabia Immuno-oncology Clinical Trials Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Medpace Revenue Growth Rate in Immuno-oncology Clinical Trials Business (2019-2024)
Figure 47. Novartis Revenue Growth Rate in Immuno-oncology Clinical Trials Business (2019-2024)
Figure 48. Exscientia Revenue Growth Rate in Immuno-oncology Clinical Trials Business (2019-2024)
Figure 49. Syneous Health Revenue Growth Rate in Immuno-oncology Clinical Trials Business (2019-2024)
Figure 50. AstraZeneca Revenue Growth Rate in Immuno-oncology Clinical Trials Business (2019-2024)
Figure 51. ICON plc Revenue Growth Rate in Immuno-oncology Clinical Trials Business (2019-2024)
Figure 52. IQVIA Holdings Revenue Growth Rate in Immuno-oncology Clinical Trials Business (2019-2024)
Figure 53. BioNtech Revenue Growth Rate in Immuno-oncology Clinical Trials Business (2019-2024)
Figure 54. Covance, Inc. Revenue Growth Rate in Immuno-oncology Clinical Trials Business (2019-2024)
Figure 55. IO BIOTECH Revenue Growth Rate in Immuno-oncology Clinical Trials Business (2019-2024)
Figure 56. Bottom-up and Top-down Approaches for This Report
Figure 57. Data Triangulation
Figure 58. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
